GO
Loading...

Takeover Bids

More

  • June 23- Augusta Resource Corp said it agreed to be bought by HudBay Minerals Inc after the company raised its offer to buy Augusta shares it does not already own. The offer price of about C $3.56 per Augusta common share represents a premium of about 11 percent to Augusta's Friday close on the Toronto Stock Exchange.

  • Augusta agrees to revised HudBay takeover offer Monday, 23 Jun 2014 | 7:10 AM ET

    June 23- Augusta Resource Corp said it agreed to be bought by HudBay Minerals Inc after the company raised its offer to buy Augusta shares it does not already own. The revised offer values Augusta at about C $555 million, HudBay said.

  • LONDON, June 20- The FTSEurofirst 300 climbed to a 6-1/ 2- year high on Friday and recorded its 10th straight week of gains, with analysts saying that expectations of a pick-up in merger and acquisition activity will further boost sentiment.

  • Cramer: AbbVie-Shire driven by inversion     Friday, 20 Jun 2014 | 9:07 AM ET

    British drug maker Shire has rejected a $46 billion takeover offer from U.S. based AbbVie. CNBC's Jim Cramer discusses the latest attempt by a U.S. health care company to tap into the low foreign tax rate.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- The pan-European FTSEurofirst 300 index reached a 6 1/ 2- year high on Friday as the drugmaker Shire rallied on a takeover offer, putting the index on track for a 10th straight week of gains. Shire climbed 11.4 percent to 41.65 pounds after AbbVie confirmed it had made an offer to acquire it.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • Shire props up European shares on bid hopes Friday, 20 Jun 2014 | 3:56 AM ET

    *Shire up 13 percent as AbbVie confirms rejected bid. LONDON, June 20- A rally in drugmaker Shire helped European bourses hold onto gains on Friday on news the British firm had been the target of a takeover bid from U.S. rival AbbVie. Shares in Shire rose 13 percent to 42.31 pounds after AbbVie confirmed it had made a bid approach, which was rejected by Shire's board.

  • LONDON, June 20- British drugmaker Shire has rejected a takeover offer from AbbVie Inc which would have valued the group at around 27 billion pounds, the U.S. firm said on Friday.

  • *U.S. group says alliance proposal agreed with Alstom management. PARIS, June 19- U.S. conglomerate General Electric reshaped its offer for the power assets of Alstom on Thursday to propose an alliance based on 50:50 joint ventures that would ringfence sensitive nuclear activities.

  • SYDNEY/ JOHANNESBURG, June 19- Australian retailer David Jones Ltd has postponed a shareholder vote on a $2 billion takeover bid from South Africa's Woolworths after Australian billionaire Solomon Lew amassed a stake that could scupper the deal.

  • Valeant goes hostile in bid for Allergan     Tuesday, 17 Jun 2014 | 8:37 AM ET

    Valeant says it will launch an exchange offer to Allergan shareholders, reports CNBC's Meg Tirrell.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • LONDON, June 16- London- listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.

  • NEW YORK, June 16- Morgan Stanley, an adviser to Valeant Pharmaceuticals International Inc in its $53 billion hostile bid for Allergan Inc, initially tried to get hired by Allergan and in its pitch called the unsolicited bidder a "house of cards", according to Allergan.

  • NEW YORK, June 16- Morgan Stanley, an adviser to Valeant Pharmaceuticals International Inc in its $53 billion hostile bid for Allergan Inc, initially tried to get hired by Allergan and in its pitch called the unsolicited bidder a "house of cards", according to Allergan.

  • TOKYO, June 16- Mitsubishi Heavy Industries' involvement in Siemens' bid for the power assets of France's Alstom fits in with the Japanese company's plans to build a global presence after a recent major reorganization of its business.

  • June 13- William Ackman's Pershing Square Capital Management on Friday it filed a lawsuit against Allergan Inc seeking confirmation that its request to hold a special meeting of Allergan shareholders would not trigger poison pill takeover defense. Ackman and Valeant Pharmaceuticals International are pursuing in a hostile takeover of Allergan.

  • *Mitsubishi and France would take equal stakes in Alstom- unions. MUNICH/ PARIS, June 13- Germany's Siemens and Japan's Mitsubishi Heavy Industries are putting the finishing touches on a joint offer for Alstom's turbine businesses that includes a cash element of roughly 9 billion euros, sources close to the bidders said.

  • Siemens and Mitsubishi finalize Alstom offer Friday, 13 Jun 2014 | 12:33 PM ET

    *Siemens would acquire gas turbines from Alstom, sources say. MUNICH/ PARIS, June 13- Germany's Siemens and Japan's Mitsubishi Heavy Industries are putting the finishing touches on a joint offer for Alstom's turbine businesses that includes a cash element of roughly 9 billion euros, sources close to the bidders said.